$281 Million is the total value of Athyrium Capital Management, LP's 10 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Progenity Inc.note 7.250% 12/0 | $73,701,000 | -2.3% | 103,500,000 | 0.0% | 26.20% | -2.5% | ||
AMYT | Amryt Pharma PLCsponsored ads | $73,250,000 | -23.4% | 8,857,268 | 0.0% | 26.04% | -23.6% | |
PROG | Progenity Inc. | $34,633,000 | -44.5% | 29,855,847 | 0.0% | 12.31% | -44.7% | |
OSMT | RVL PHARMACEUTICALS PLC | $13,772,000 | +56.5% | 8,148,832 | 0.0% | 4.90% | +56.0% | |
REPH | Societal CDMO Inc. | $3,964,000 | +5.3% | 2,202,420 | 0.0% | 1.41% | +4.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Amryt Pharma PLC | 10 | Q1 2023 | 46.3% |
Progenity Inc. | 9 | Q4 2022 | 69.2% |
Progenity Inc. | 8 | Q3 2023 | 39.2% |
RVL PHARMACEUTICALS PLC | 8 | Q3 2023 | 11.5% |
Societal CDMO Inc. | 8 | Q4 2022 | 3.1% |
Omeros Corp | 7 | Q3 2023 | 39.3% |
CAREMAX INC | 7 | Q4 2022 | 27.5% |
Omeros Corp | 7 | Q3 2023 | 9.9% |
PUMA BIOTECHNOLOGY INC | 7 | Q3 2023 | 4.2% |
AEGERION PHARMACEUTICALS INC | 6 | Q1 2019 | 88.7% |
View Athyrium Capital Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
PROGENITY, INC. | August 27, 2021 | 4,211,977 | 2.7% |
View Athyrium Capital Management, LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-16 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR/A | 2023-05-16 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
View Athyrium Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.